CN
  • Home
  • About Us
  • News
  • R&D innovation

    Back

    Biopharmaceuticals
    Functional ingredients
    Nutritional products
  • Product Center

    Back

    Biopharmaceuticals
    Functional ingredients
    Nutritional products
  • Internationalization
  • Development
Back
2023/ 10/24

新诺威三季度业绩出炉

10月24日,新诺威(300765.SZ)公布三季度报告。

公司前三季度营业收入19.02亿元,同比增长0.46%;净利润5.83亿元,同比增长12.74%;扣非净利润5.76亿元,同比增长25.66%。

< Previous Article:【媒体报道】控股巨石生物,新诺威添增长引擎 Next Article:果维康连续十五年荣获中国药店“店员推荐率最高品牌”奖

Related News

  • 2026/10/29
    2026 ESMO | Prof. Guiling Li: Enlonstobart plus chemotherapy induction followed by concurrent chemoradiotherapy for locally advanced cervical cancer demonstrates favorable efficacy and safety — deep tumor regression during induction enables radiotherapy dose reduction and field shrinking
  • 2026/10/28
    2026 ESMO: First-in-Human Phase I/II Study Results of CSPC’s Innovative SYS6090 (JMT108) in Advanced Solid Tumors Presented
  • 2026/10/09
    Phase I study results of monotherapy with SYS6002 (CSPC Innovation) for advanced cervical cancer presented as a rapid oral report at the 2026 International Gynecologic Cancer Society Global Annual Meeting
  • 2026/09/15
    CSPC Innovation’s SYS6010 Presents Research Findings at the 2026 World Conference on Lung Cancer (WCLC)
News
About Us Contact Us Site Map Legal terms

Phone: 0311-85408700

Address:No. 62 Zhangju Road, Luancheng District, Shijiazhuang City, Hebei Province

©2024 CSPC INNOVATION PHARMACEUTICAL CO., LTD. 冀ICP备05003393号-7 PowerBy XinHongRu